Valid Ghana · FDA Ghana

AZIMOX 250 CAPLETS

ACELASOLAMIDE

FDA/SD.02-4154 CAPLETS 250mg

What it does

Acelasolamide is a medication used to treat certain types of seizures.

Commonly used for: seizures (epilepsy), mood disorders

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
FDA/SD.02-4154
Registration date
2017-11-01
Expiry date
2027-12-31
Status
Valid
Active ingredient
ACELASOLAMIDE
Dosage form
CAPLETS
Strength
250mg
Pack size
-
Therapeutic class
-
Manufacturer / MAH
Ernest Chemists
Country of origin
-
Manufacturer location
Ring Road Central, Accra, Ghana

Source: Food and Drugs Authority · fetched 2026-04-18 08:37:39 · updated 2026-10-20 04:00:12

Disclaimer: This information is sourced from Food and Drugs Authority (Ghana). Always consult a qualified healthcare professional before using any medication.

About this medicine

Acelasolamide is a medication used to treat certain types of seizures.

What it treats

  • seizures (epilepsy)
  • mood disorders

How it works

Acelasolamide helps to stabilize electrical activity in the brain, which can reduce the frequency of seizures.

Who it's for

This medication is prescribed for individuals with epilepsy or those experiencing mood disorders.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: acelasolamide

Acetazolamide is a carbonic anhydrase inhibitor that is primarily used as a diuretic and in the treatment of certain conditions such as glaucoma, epilepsy, altitude sickness, and metabolic alkalosis. It facilitates the excretion of bicarbonate in the urine, leading to increased urine output and decreased fluid retention.

Indications

  • Glaucoma
  • Epilepsy (as an adjunctive therapy)
  • Altitude sickness
  • Metabolic alkalosis
  • Diuretic for certain conditions

Dosage

Children: Refer to the BNF for Children for appropriate dosing information.

Adults: Refer to the BNF for appropriate dosing information.

Mechanism of action

Acetazolamide works by inhibiting the enzyme carbonic anhydrase, which decreases the conversion of carbon dioxide and water into bicarbonate and protons. This action leads to a reduction in bicarbonate reabsorption in the proximal tubule of the nephron, resulting in increased bicarbonate and sodium excretion, diuresis, and a decrease in intraocular pressure in the eye.

Pharmacodynamics

The diuretic effect of acetazolamide is dose-dependent and is characterized by increased urinary bicarbonate, sodium, and water excretion. Its action reduces intraocular pressure by decreasing the production of aqueous humor in the eye. Additionally, acetazolamide can help in the management of metabolic alkalosis by promoting bicarbonate excretion.

Pharmacokinetics

Acetazolamide is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 2 to 4 hours after oral administration. It has a volume of distribution of about 0.2 to 0.3 L/kg and is approximately 90% protein-bound. The drug is metabolized primarily in the liver and excreted in urine, mostly in unchanged form. Its half-life ranges from 3 to 6 hours, but it can be prolonged in patients with renal impairment.

Contra-indications

  • Hypersensitivity to acetasolamide or any of its components
  • Severe renal impairment
  • Adrenal insufficiency

Adverse effects

  • Metabolic acidosis
  • Hypokalemia
  • Drowsiness
  • Paraesthesia
  • Nausea
  • Vomiting
  • Anorexia
  • Decreased appetite
  • Fatigue
  • Kidney stones
  • Allergic reactions

Interactions

  • Concurrent use with other carbonic anhydrase inhibitors may increase the risk of adverse effects
  • Caution with diuretics that may cause electrolyte imbalance
  • May enhance the effects of other CNS depressants

Precautions

  • Use with caution in patients with liver disease
  • Monitor electrolyte levels regularly
  • Assess renal function before initiating therapy
  • Consider potential for cross-reactivity in patients allergic to sulfonamides

Pregnancy

Acelasolamide is classified as a Category C drug. Risk cannot be ruled out. Use only if clearly needed.

Breast-feeding

It is not known whether acetasolamide is excreted in human milk. Caution is advised when administered to breastfeeding women.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

  • Oral tablets
  • Extended-release capsules

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.